Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 314

Similar articles for PubMed (Select 21338707)

1.

Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.

Wudhikarn K, Brunstein CG, Bachanova V, Burns LJ, Cao Q, Weisdorf DJ.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1497-504. doi: 10.1016/j.bbmt.2011.02.009. Epub 2011 Feb 18.

2.

Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.

Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH, Shustov AR, Flowers ME, O'Donnell P, Sandmaier BM, Storb RF, Gopal AK.

Biol Blood Marrow Transplant. 2011 Oct;17(10):1537-45. doi: 10.1016/j.bbmt.2011.03.010. Epub 2011 Apr 12.

4.

Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.

Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P, Stein A, Smith E, Planas I, Kashyap A, Spielberger R, Fung H, Krishnan A, Bhatia R, Wong KK, Somlo G, Margolin K, Chow W, Sniecinski I, Vora N, Slovak M, Niland JC, Forman SJ.

Clin Lymphoma. 2000 Jun;1(1):46-54.

PMID:
11707813
5.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
6.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE.

Biol Blood Marrow Transplant. 2006 Jul;12(7):703-11.

8.

Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.

Shustov A.

Best Pract Res Clin Haematol. 2013 Mar;26(1):89-99. doi: 10.1016/j.beha.2013.04.008. Epub 2013 May 25. Review.

PMID:
23768643
9.

Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.

Bishop MR, Dean RM, Steinberg SM, Odom J, Pollack SM, Pavletic SZ, Sportes C, Gress RE, Fowler DH.

Cancer. 2010 Feb 15;116(4):852-62. doi: 10.1002/cncr.24845.

10.

Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.

Zain J, Palmer JM, Delioukina M, Thomas S, Tsai NC, Nademanee A, Popplewell L, Gaal K, Senitzer D, Kogut N, O'Donnell M, Forman SJ.

Leuk Lymphoma. 2011 Aug;52(8):1463-73. doi: 10.3109/10428194.2011.574754. Epub 2011 Jun 24.

11.

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).

Haematologica. 2007 May;92(5):627-34.

12.

T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.

Kenkre VP, Horowitz S, Artz AS, Liao C, Cohen KS, Godley LA, Kline JP, Smith SM, Stock W, van Besien K.

Leuk Lymphoma. 2011 Feb;52(2):214-22. doi: 10.3109/10428194.2010.538777. Epub 2010 Dec 10.

13.

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N.

Haematologica. 2012 Feb;97(2):310-7. doi: 10.3324/haematol.2011.045757. Epub 2011 Oct 11.

14.

Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.

Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, Rodriguez J, von Wolff B, Gajewski J, Cabanillas F, Champlin R.

Ann Oncol. 1999 Nov;10(11):1293-9.

15.

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

Piñana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL, Vazquez L, Arranz R, Tomás JF, Sampol A, Solano C, Delgado J, Sierra J, Caballero D; GELTAMO Group.

Haematologica. 2010 Jul;95(7):1176-82. doi: 10.3324/haematol.2009.017608. Epub 2010 Jan 27.

16.

Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma.

Doocey RT, Toze CL, Connors JM, Nevill TJ, Gascoyne RD, Barnett MJ, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJ, Smith CA, Song KW.

Br J Haematol. 2005 Oct;131(2):223-30.

PMID:
16197454
17.

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.

Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman SJ, McSweeney PA, Maziarz RT, Pulsipher MA, Agura ED, Wade J, Sorror M, Maloney DG, Sandmaier BM.

J Clin Oncol. 2006 Sep 1;24(25):4150-7. Epub 2006 Aug 8.

18.

Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.

Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM.

Biol Blood Marrow Transplant. 2009 May;15(5):547-53. doi: 10.1016/j.bbmt.2009.01.010. Epub 2009 Mar 9.

19.

Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.

Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, Milpied N, Socie G, Browne P, Lenhoff S, Sanz MA, Aljurf M, Mohty M, Rocha V; Immunotherapy Subcommittee of Acute Leukemia Working Party.

Leukemia. 2012 Jun;26(6):1211-7. doi: 10.1038/leu.2011.351. Epub 2012 Jan 31.

PMID:
22290066
20.

Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.

Maruyama D, Fukuda T, Kato R, Yamasaki S, Usui E, Morita-Hoshi Y, Kim SW, Mori S, Heike Y, Makimoto A, Tajima K, Tanosaki R, Tobinai K, Takaue Y.

Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41. Epub 2007 May 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk